Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence
Mrunal Vitthal Wanjale,Vishnu Sunil Jaikumar,K C Sivakumar,Riya Ann Paul,Jackson James,G S Vinod Kumar,KC Sivakumar,GS Vinod Kumar
DOI: https://doi.org/10.2147/IJN.S348559
IF: 7.033
2022-05-16
International Journal of Nanomedicine
Abstract:Mrunal Vitthal Wanjale, 1, 2 Vishnu Sunil Jaikumar, 3 KC Sivakumar, 4 Riya Ann Paul, 2, 5 Jackson James, 5 GS Vinod Kumar 1 1 Nano Drug Delivery Systems (NDDS), Cancer Biology Division, Rajiv Gandhi Centre for Biotechnology, Thycaud P.O, Thiruvananthapuram, Kerala, 695014, India; 2 Research Scholar, Department of Biotechnology, Faculty of Applied Sciences & Technology, University of Kerala, Thiruvananthapuram, Kerala, 695581, India; 3 Animal Research Facility, Rajiv Gandhi Centre for Biotechnology, Thycaud P.O, Thiruvananthapuram, Kerala, 695014, India; 4 Distributed Information Sub-Centre (Bioinformatics Centre), Bio-Innovation Center (BIC), Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, 695014, India; 5 Neuro-Stem Cell Biology Lab, Rajiv Gandhi Centre for Biotechnology, Thycaud P.O, Thiruvananthapuram, Kerala, 695014, India Correspondence: GS Vinod Kumar, Tel +91 471 2781217, Fax +91 471 2348096, Email Purpose: The brain, protected by the cranium externally and the blood–brain barrier (BBB) internally, poses challenges in chemotherapy of aggressive brain tumors. Maximal tumor resection followed by radiation and chemotherapy is the standard treatment protocol; however, a substantial number of patients suffer from recurrence. Systemic circulation of drugs causes myelodysplasia and other side effects. To address these caveats, we report facile synthesis of a polyester-based supramolecular hydrogel as a brain biocompatible implant for in situ delivery of hydrophobic drugs. Methods: Polycaprolactone-diol (PCL) was linked to polyethyleneglycol-diacid (PEG) via an ester bond. In silico modeling indicated micelle-based aggregation of PCL-PEG co-polymer to form a supramolecular hydrogel. Brain biocompatibility was checked in Sprague Dawley rat brain cortex with MRI, motor function test, and histology. Model hydrophobic drugs carmustine and curcumin entrapment propelled glioma cells into apoptosis-based death evaluated by in vitro cytotoxicity assays and Western blot. In vivo post-surgical xenograft glioma model was developed in NOD-SCID mice and evaluated for efficacy to restrict aggressive regrowth of tumors. Results: 20% (w/v) PCL-PEG forms a soft hydrogel that can cover the uneven and large surface area of a tumor resection cavity and maintain brain density. The PCL-PEG hydrogel was biocompatible, and well-tolerated upon implantation in rat brain cortex, for a study period of 12 weeks. We report for the first time the combination of carmustine and curcumin entrapped as model hydrophobic drugs, increasing their bioavailability and yielding synergistic apoptotic effect on glioma cells. Further in vivo study indicated PCL-PEG hydrogel with a dual cargo of carmustine and curcumin restricted aggressive regrowth post-resection significantly compared with control and animals with intravenous drug treatment. Conclusion: PCL-PEG soft gel-based implant is malleable compared with rigid wafers used as implants, thus providing larger surface area contact. This stable, biocompatible, supramolecular gel without external crosslinking can find wide applications by interchanging formulation of various hydrophobic drugs to ensure and increase site-specific delivery, avoiding systemic circulation. Graphical Keywords: glioma, drug, delivery, brain, tumor, implant, surgery, hydrogel Graphical Intracranial implants for chemotherapeutic delivery had revolutionized glioma therapy once, since the conception of bis-chloroethyl nitrosourea (BCNU) releasing wafers in 1993. 1,2 Polymeric implants can be delivered post-surgically in the tumor resection cavities, which helps in immediate drug release to tackle the relapse arising from the remnant glioma cells. A study by Choucair et al. reported that over 90% of glioblastoma multiforme (GBM) patients suffer from recurrence at the site of the primary tumor, with 5% of patients showing multiple lesions after treatment. 3,4 In a prospective study of 222 randomised, placebo-controlled glioma patients, it was found that polymer implant-based chemotherapy directly to brain tumors at the time of surgery could be a safe and effective treatment for recurrent malignant gliomas. 5 Many researchers have noted these advantages and worked upon implant-based systems to deliver several drugs such as paclitaxel, camptothecin, and temozolomide, in animal models. 6–8 However, the current treatment strategy includes oral and IV modes of treatment that lead to systemic circulation of DNA alkylating chemotherapy drugs, potentially causing treatment-induced myelodysplasia. 9,10</sup -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology